Biosensor based system for detection of viruses
ELISHA Systems Ltd, Wakefield, West Yorkshire, United Kingdom
Diagnostic technologies for identification of SARS-CoV-2 from human nasal, buccal, or saliva samples
Tech Brief: An affinity biosensor system, configured as single disposable tests together with a small electronic reader is presented as a route to detect and quantify whole virus particles. We have shown: 1) a COVID-19 pseudovirus can be detected in 5 to 10 minutes and 2) COVID-19 antibodies can be detected.
Small to Medium Enterprise
FIGURES OF MERIT Value Proposition: A portable, simple, compact system to detect SARS-COV-2 will impact almost every industry and group World-wide, much the same as the analogous blood-glucose test did in the 1990’s. In addition because the system can be adapted to detect ANY virus (or bacteria or protein) i.e. it is fully future proofed, the potential impact in multiple industries, countries and populations is extremely large. Commercial partner benefits – successful commercial production and marketing will bring huge profits. The biosensor market is predicted to be worth around $35 billion by 2025 with the largest growth areas being point-of-care and home testing. The cumulative annual growth rate (CAGR) is estimated to be 7.9% to achieve this growth. The biosensor system described combines antibody detection into an electronic biosensor, thereby being comparable to the blood glucose biosensor developed in the 1980’s and brought to market in the 1990’s. The glucose biosensor market for diabetics was worth $18 billion world-wide in 2019. Based on these figures a simple, rapid, point-of-care antibody biosensor system should anticipate a market size of at least $20 billion if not more as the market develops. Expanding the system to multiple analytes will expand the market considerably